PMID- 32650038 OWN - NLM STAT- MEDLINE DCOM- 20210625 LR - 20210625 IS - 1879-0984 (Electronic) IS - 0166-0934 (Linking) VI - 284 DP - 2020 Oct TI - Replacing the decoy epitope of PCV2 capsid protein with epitopes of GP3 and/or GP5 of PRRSV enhances the immunogenicity of bivalent vaccines in mice. PG - 113928 LID - S0166-0934(20)30180-4 [pii] LID - 10.1016/j.jviromet.2020.113928 [doi] AB - Porcine circovirus type 2 (PCV2) is the causative agent of postweaning multisystemic wasting syndrome (PMWS), porcine dermatitis and nephropathy syndrome (PDNS), and reproductive failure and causes economic losses in the domestic swine industry. The decoy epitope (169-180 amino acid (aa)) of the PCV2 capsid (Cap) protein is an immunodominant epitope and diverts the immune response away from protective epitopes. The mixed infection of PCV2 and porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most common co-infections in the pig industry and shows more severe clinical symptoms. Linear B-cell antigenic epitopes of PRRSV GP3 epitope Ⅰ (61-72aa) and PRRSV GP5 epitope Ⅳ (187-200aa) efficiently elicited neutralizing antibodies against PRRSV. The recombinant baculovirus expressing the Cap protein (Bac-Cap) was modified by replacing the decoy epitope of the Cap protein with either the PRRSV GP3 epitope Ⅰ, the PRRSV GP5 epitope Ⅳ, or the PRRSV GP3 epitope Ⅰ- GP5 epitope Ⅳ to produce the recombinant baculoviruses Bac-Cap-GP3, Bac-Cap-GP5 and Bac-Cap-GP35. The four recombinant baculoviruses were successfully established and characterized as demonstrated with western blot analysis and immunofluorescence assay. Immunogenicities of the four recombinant baculoviruses in mice were tested in sera harvested at 21 and 42 days post-primary immunization. The titers of antibodies in the sera were determined by a PCV2-specific enzyme-linked immunosorbent assay (ELISA) and a serum neutralization assay. The serum IFN-gamma levels were measured by indirect ELISA. The results showed that Bac-Cap-GP3, Bac-Cap-GP5, and Bac-Cap-GP35 elicited higher GP3/GP5 and Cap antibody titers than the Bac-Cap. Virus neutralization test also confirmed that the serum from the Bac-Cap-GP3 immunized mice had high levels of the both PCV2 and PRRSV neutralization antibodies. These findings collectively demonstrated that substituting the decoy epitope of the PCV2 capsid substituted with PRRSV epitopes could be developed into an effective vaccine against PCV2. CI - Copyright (c) 2020. Published by Elsevier B.V. FAU - Jung, Bo-Kyoung AU - Jung BK AD - Department of Clinical Laboratory Science, Catholic University of Pusan, Busan, 48513, Republic of Korea; Libentech Co. LTD, C-722 Daedeok BIZ Center, Techno 4-ro, 17 Yuseong-gu, Daejeon, 34013, Republic of Korea. Electronic address: jbok90@hanmail.net. FAU - Kim, Hye-Ran AU - Kim HR AD - Department of Clinical Laboratory Science, College of Medical Sciences, Daegu Haany University, Daegu, 38610, Republic of Korea. Electronic address: hrkim@dhu.ac.kr. FAU - Jang, Huyn AU - Jang H AD - Libentech Co. LTD, C-722 Daedeok BIZ Center, Techno 4-ro, 17 Yuseong-gu, Daejeon, 34013, Republic of Korea. Electronic address: vacchyun@naver.com. FAU - Chang, Kyung-Soo AU - Chang KS AD - Department of Clinical Laboratory Science, Catholic University of Pusan, Busan, 48513, Republic of Korea. Electronic address: kschang@cup.ac.kr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200707 PL - Netherlands TA - J Virol Methods JT - Journal of virological methods JID - 8005839 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (Capsid Proteins) RN - 0 (Cytokines) RN - 0 (Epitopes, B-Lymphocyte) RN - 0 (Immunodominant Epitopes) RN - 0 (Vaccines, Combined) RN - 0 (Vaccines, Virus-Like Particle) RN - 0 (Viral Envelope Proteins) RN - 0 (Viral Vaccines) SB - IM MH - Animals MH - Antibodies, Neutralizing/blood MH - Antibodies, Viral/blood MH - Baculoviridae/genetics MH - Capsid Proteins/genetics/*immunology MH - Circovirus/*immunology MH - Cytokines/blood MH - Epitopes, B-Lymphocyte MH - Immunodominant Epitopes MH - Mice MH - Porcine respiratory and reproductive syndrome virus/*immunology MH - Vaccination MH - Vaccines, Combined/immunology MH - Vaccines, Virus-Like Particle/immunology MH - Viral Envelope Proteins/genetics/*immunology MH - Viral Vaccines/*immunology OTO - NOTNLM OT - Epitope OT - PCV2 OT - PRRSV OT - Recombinant baculovirus OT - Subunit vaccine OT - VLP EDAT- 2020/07/11 06:00 MHDA- 2021/06/29 06:00 CRDT- 2020/07/11 06:00 PHST- 2019/04/19 00:00 [received] PHST- 2020/04/15 00:00 [revised] PHST- 2020/07/04 00:00 [accepted] PHST- 2020/07/11 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2020/07/11 06:00 [entrez] AID - S0166-0934(20)30180-4 [pii] AID - 10.1016/j.jviromet.2020.113928 [doi] PST - ppublish SO - J Virol Methods. 2020 Oct;284:113928. doi: 10.1016/j.jviromet.2020.113928. Epub 2020 Jul 7.